New anti-cancer drug

The new anti-cancer drug, OMO-1, was given to the first cancer patient in the world last week in Oxford University’s Early Phase trials unit. Dr Sarah Blagden (Oxford’s ECMC lead and Director of the Early Phase Trials Unit) is Chief Investigator of this Phase I/II study of the combined c-MET/ OCT-1 inhibitor OMO-1 that was outlicenced from Janssen Pharmaceutica to be developed by the Belgian life science company OCTIMET Oncology NV.

Congratulations to student prize winners

The 5th Annual Oncology Student Symposium held at St Anne’s College on Thursday, 13 July was a great success with  a full day of talks in the Mary Ogilvie lecture theatre and a poster session in the marquee within the beautiful surroundings of the St Anne’s Quad.   The judges commented on how high the standard of work was this year, making their decision all the more challenging.

The prizes for the four categories were awarded as follows: 

Oxford collaborative science opens the way for a new drug for bowel cancer patients across the UK

Today a new drug will become available for patients with bowel cancer as part of a national clinical trial; based on a scientific discovery made only two years ago at the University of Oxford. A yeast genetics research group led by Professor Tim Humphrey in Oxford discovered an Achilles heel of certain cancer cells – mutations in a gene called SETD2. Prof Humphrey and his team showed that cancer cells with a mutated SETD2 gene were killed by an experimental drug being developed by Astra Zeneca called AZD1775 which inhibits a protein called WEE1.

Green Impact Team silver award

Congratultions to everyone in Old Road Campus Research Building’s Green Impact team, which includes various members of staff from Departments within the Building including Oncology, and also to everyone in the building who has helped achieve a silver award for environmental sustainability projects.

The announcement was made at a recent ceremony, held at the Sheldonian Theatre, and the award will be displayed in the reception.  

FOXFIRE Combined Analysis

FOXFIRE Combined Analysis indicates no benefit in overall survival from adding selective internal radiotherapy [SIRT] to first-line oxaliplatin-based chemotherapy for metastatic colorectal cancer.

Secondary analyses confirm improved control of liver metastases with liver-directed SIRT and show clinical benefit in patients with liver metastases originating from difficult-to-treat right-sided colon cancer.

100km non-stop in 24 hours

Five members of Professor Len Seymour's laboratory (Arthur Dyer, Sally Frost, Sophie Owen, Tzveta Pokrovska and Ellie Scott) are limbering up to walk 100km non-stop in 24 hours over the August bank holiday to raise money for Cancer Research UK, Martlet's Hospice and the Red Cross.

If you have any spare money and would like to support them please visit the Just Giving page – all donations are greatly appreciated. 

In advance of any donations received the “Angels” thank you for your support.

Cancer Research UK Boat Race

Joshua Bugajski (Stroke 4), an MSc Oncology student in Katherine Vallis’ group was part of Oxford’s winning team on Sunday, 2 April when they cruised to victory in the 2017 Cancer Research UK boat race against Cambridge. 

Oxford won the toss and chose the Surrey station.  The crew took an early lead over Cambridge and this was Oxford’s 80th win in the event’s history – just 2 behind their rivals. 

(photo credited to Getty Images)



About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.
Subscribe to RSS - News